facebook pixel

News

Are Psychedelics the Future of Pain Relief?

Are Psychedelics the Future of Pain Relief?

For more than 15 years, Ainslie Course suffered from one of the most intense pains known to humans: cluster headaches. Sometimes nicknamed "suicide headaches", her main symptom was an excruciating pain that suddenly surrounded one eye in debilitating bouts of attacks.

read more
Small Doses of Psychedelics for Cluster Headaches

Small Doses of Psychedelics for Cluster Headaches

One understudied condition for which small doses of psychedelic substances such as psilocybin may be beneficial is cluster headache. As founder and executive director of the advocacy group Clusterbusters, I have seen firsthand, as a patient and an activist, that,...

read more
Could Psilocybin be the Next Migraine and Cluster Headaches Treatment?

Could Psilocybin be the Next Migraine and Cluster Headaches Treatment?

Migraine and cluster headache (CH) are both ongoing conditions that severely impact a patient’s quality of life and are significant causes of disability.

Although treatments are available for both conditions, medications have been known to be ineffective and cause unpleasant side-effects in a significant number of patients.

Evidence has shown that psilocybin – the psychoactive ingredient in magic mushrooms – alongside other drugs which interact with the 5-HT2A receptor, like LSD, have long-lasting effects reducing migraine and CH frequency in patients.

read more

Demoralization predicts suicidality in patients with cluster headache

The particular characteristics of cluster headache (CH) impart a marked burden on its patients. CH is the most common trigeminal autonomic cephalalgia, characterized by recurrent disabling attacks of unilateral retroorbital pain accompanied by ipsilateral autonomic symptoms such as lacrimation, ptosis, nasal congestion and/ or facial sweating. Headache attacks recur over periods of weeks to months separated by attack-free remission periods lasting months to years; this episodic form of CH comprises approximately 80% of cases.

read more

Mark’s Newsletter Archive (pending)

 

Skip to content